At the 2026 SCOPE Summit, AI discussions shifted from research question to operational reality, but most organizations still run disconnected AI pilots rather than integrated systems. The distinction matters: AI-augmented operations use tools for specific tasks, while AI-native architecture lets AI coordinate decision flows across workflows with human oversight. Evidence is emerging. A JAMA trial of AI-assisted screening at Mass General Brigham nearly doubled enrollment rates versus manual review. Cleveland Clinic's AI eligibility system achieved 96% accuracy across structured and unstructured EHR data. McKinsey reported a pharma deployment that cut clinical study report drafting time from twelve weeks to six. The foundation is shifting too. ICH M11, effective June 11, 2026, establishes machine-readable protocol standards across FDA, EMA, and PMDA. Structured protocol data enables automated updates to eCRFs, IRT builds, and eligibility logic, reducing manual transcription cascades. For site teams, this means faster activation, fewer amendment delays, and coordination systems that flag issues before they escalate. The operational pressure is real: Phase III trials now cost $55,716 per day on average, up 55% from prior benchmarks, and site activation rates in North America have dropped to 62%.